Clinical trials will advance treatment of COVID-19 infection. September 11, 2023, Beijing, China - Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in.
Sinovac Biotech Ltd. SINOVAC or the Company NASDAQ SVA a leading provider of biopharmaceutical products in China announced that the Company has completed the phase I clinical trial for its broadspectrum neutralizing antibody product the AntiCOVID19 Antibody SA55 Injection SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
Sinovac Announces Change of Legal Representative of Sinovac Beijing tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Sinovac Biotech Ltd. , a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023.
First Half of 2023. -Today at 06:03 am- MarketScreener
Supplemental Submission Pursuant to Item 16I of Form 20-F Sinovac Biotech Ltd. is submitting via EDGAR the following information as required under Item 16I of Form 20-F in. | May 1, 2023